Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1644-1653

  Petitprez, Amélie ^a,b,c,d   Poindessous, Virginie ^a,b,c   Ouaret, Djamila ^a,b,c   Regairaz, Marie ^e   Bastian, Gérard ^c,f   Guérin, Eric ^g   Escargueil, Alexandre E ^a,b,c   Larsen, Annette K ^a,b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cell cycle dynamics; Colorectal cancer; Irinotecan; Microsatellite instability; Resistance

Indexed keywords

CHECKPOINT KINASE 1; FIRTECAN; IRINOTECAN;

ARTICLE; CELL CYCLE; CHROMOSOMAL INSTABILITY; COLON CANCER; FLOW CYTOMETRY; GEL ELECTROPHORESIS; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL CYCLE; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HUMANS; MICROSATELLITE INSTABILITY; S PHASE;

EID: 84876009924     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1868     Document Type: Article

References (52)

1. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 18: 5077-5082, 1989. (Pubitemid 19239347)
2. Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L and Bigg DC: Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 7: 2961-2967, 2001. (Pubitemid 32691941)
3. Wu J, Yin MB, Hapke G, Tóth K and Rustum YM: Induction of biphasic DNA double-strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol Pharmacol 4: 742-748, 2002. (Pubitemid 34273153)
4. Regairaz M, Zhang YW, Fu H, Agama KK, Tata N, Agrawal S, Aladjem MI and Pommier Y: Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol 195: 739-749, 2011.
5. Horwitz SB and Horwitz MS: Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33: 2834-2836, 1973.
6. Cheng MF, Chatterjee S and Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269-279, 1994. (Pubitemid 24329594)
7. Huang X, Traganos F and Darzynkiewicz Z: DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 6: 614-619, 2003.
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 13: 905-914, 2000.
9. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 9209: 1041-1047, 2000. (Pubitemid 30162806)
10. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature 6712: 643-649, 1998. (Pubitemid 29003936)
11. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337, 2012.
12. Jiricny J: The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 5: 335-346, 2006.
13. Jacob S, Aguado M, Fallik D and Praz F: The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 17: 6555-6562, 2001. (Pubitemid 32783264)
14. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C, Sabourin JC, Ducreux M and Praz F: Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 18: 5738-5744, 2003. (Pubitemid 37187470)
15. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF and Saijo N: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 18: 5919-5924, 1990. (Pubitemid 20331400)
16. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 18: 4559-4563, 1999. (Pubitemid 29428958)
17. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD and Kohno S: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 5: 1216-1223, 2001. (Pubitemid 32917772)
18. Rasheed ZA and Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22: 7296-7304, 2003. (Pubitemid 37487161)
19. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB and Johnston PG: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 6: 2158-2167, 2004. (Pubitemid 38375578)
20. Arakawa Y, Suzuki H, Saito S and Yamada H: Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol Cancer Ther 5: 502-508, 2006.
21. Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N and Yokoyama T: Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 1: 88-96, 2009.
22. Tagen M, Zhuang Y, Zhang F, Harstead KE, Shen J, Schaiquevich P, Fraga CH, Panetta JC, Waters CM and Stewart CF: P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 4: 195-201, 2010.
23. Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID and Ponzoni M: Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 19: 4809-4821, 2010.
24. Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B and Bally MB: Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (Lond) 9: 1645-1654, 2011.
25. Petitprez A and Larsen AK: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. Curr Pharm Des: Sep 7, 2012 (Epub ahead of print).
26. Poindessous V, Koeppel F, Raymond E, Comisso M, Waters S and Larsen AK: Marked activity of irofulven (MGI-114) toward human carcinoma cells: comparison with cisplatin and ecteinascidin (ET-743). Clin Cancer Res 9: 2817-2825, 2003. (Pubitemid 36842128)
27. Lemke K, Poindessous V, Skladanowski A and Larsen AK: The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 4: 1035-1042, 2004. (Pubitemid 39319476)
28. Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ and Larsen AK: Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Int J Oncol 23: 1347-1355, 2003.
29. Larsen AK, Paoletti J, Belehradek J Jr and Paoletti C: Uptake, cytofluorescence, and cytotoxicity of oxazolopyridocarbazoles (amino acid-ellipticine conjugates) in murine sarcoma cells. Cancer Res 46: 5236-5240, 1986. (Pubitemid 16008295)
30. Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK and Pierré A: Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1. Cancer Res 14: 7203-7210, 2006. (Pubitemid 44197699)
31. Rocca CJ, Poindessous V, Soares DG, Ouadrani KE, Sarasin A, Guérin E, de Gramont A, Henriques JA, Escargueil AE and Larsen AK: The NER proteins XPC and CSB, but not ERCC1, regulate the sensitivity to the novel DNA binder S23906: implications for recognition and repair of antitumor alkylators. Biochem Pharmacol 3: 335-343, 2010.
32. Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP and Guenot D: Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia- inducible factor-1alpha axis. Clin Cancer Res 15: 1297-1307, 2009.
33. Guérin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP and Guenot D: In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis. Mol Med 18: 83-94, 2012.
34. Gil-Delgado MA, Bastian G, Guinet F, Spano JP, Taillibert S, Rocher MA, Castaing D, Adam R, Urien S, Bismuth H and Khayat D: Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 27: 294-298, 2004. (Pubitemid 38737806)
35. Escargueil AE, Poindessous V, Soares DG, Sarasin A, Cook PR and Larsen AK: Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. J Cell Sci 121: 1275-1283, 2008. (Pubitemid 351753511)
36. Soares DG, Battistella A, Rocca CJ, Matuo R, Henriques JA, Larsen AK and Escargueil AE: Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906. Biochem J 1: 63-73, 2011.
37. Skladanowski A, Côme MG, Sabisz M, Escargueil AE and Larsen AK: Down-regulation of DNA topoisomerase II alpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule- interacting agents. Mol Pharmacol 68: 625-634, 2005. (Pubitemid 41206016)
38. Skladanowski A, Bozko P, Sabisz M and Larsen AK: Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 18: 2268-2275, 2007. (Pubitemid 47547705)
39. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA and Larsen AK: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 32: 13062-13067, 2007. (Pubitemid 351737593)
40. Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE and Larsen AK: Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 8: 1481-1489, 2011.
41. Poindessous V, Ouaret D, El Ouadrani K, Battistella A, Mégalophonos VF, Kamsu-Kom N, Petitprez A, Escargueil AE, Boudou P, Dumont S, Cervera P, Fléjou JF, André T, Tournigand C, Chibaudel B, de Gramont A and Larsen AK: EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin Cancer Res 20: 6522-6530, 2011.
42. Godard T, Deslandes E, Sichel F, Poul JM and Gauduchon P: Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 1-2: 47-56, 2002. (Pubitemid 35247572)
43. Hans F and Dimitrov S: Histone H3 phosphorylation and cell division. Oncogene 20: 3021-3027, 2001. (Pubitemid 32553556)
44. Pines J and Hunter T: Cyclin-dependent kinases: a new cell cycle motif? Trends Cell Biol 5: 117-121, 1991. (Pubitemid 121001662)
45. Ookata K, Hisanaga S, Okano T, Tachibana K and Kishimoto T: Relocation and distinct subcellular localization of p34cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J 5: 1763-1772, 1992.
46. Escargueil AE, Plisov SY, Skladanowski A, Borgne A, Meijer L, Gorbsky GJ and Larsen AK: Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling. FASEB J 12: 2288-2290, 2001.
47. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J and Bartek J: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 7035: 864-870, 2005. (Pubitemid 40558993)
48. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C and Halazonetis TD: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913, 2005. (Pubitemid 40559004)
49. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J and Jackson SP: ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8: 37-45, 2006. (Pubitemid 43064795)
50. Reinhardt HC and Yaffe MB: Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2 and MK2. Curr Opin Cell Biol 21: 245-255, 2009.
51. Soza S, Leva V, Vago R, Ferrari G, Mazzini G, Biamonti G and Montecucco A: DNA ligase I deficiency leads to replication-dependent DNA damage and impacts cell morphology without blocking cell cycle progression. Mol Cell Biol 29: 2032-2041, 2009.
52. Li J and Stern DF: Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 280: 12041-12050, 2005. (Pubitemid 40418523)